Prognostic models are crucial for optimal management of patients with renal cell carcinoma (RCC) after surgery. Multiple clinico-pathological models to predict cancer outcomes in these patients exist and seem to have reached their performance ceiling. Future research needs to identify new prognostic markers and to consider when and how prognostic models for RCC are implemented into practice.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Kratzer, T. B. et al. Progress against cancer mortality 50 years after passage of the National Cancer Act. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2021.5668 (2021).
Marconi, L. et al. Prevalence, disease-free, and overall survival of contemporary patients with renal cell carcinoma eligible for adjuvant checkpoint inhibitor trials. Clin. Genitourin. Cancer 19, e92–e99 (2021).
Klatte, T., Rossi, S. H. & Stewart, G. D. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World J. Urol. 36, 1943–1952 (2018).
Usher-Smith, J. A. et al. Risk models for recurrence and survival after kidney cancer: a systematic review. BJU Int. https://doi.org/10.1111/bju.15673 (2021).
Correa, A. F. et al. Predicting disease recurrence, early progression, and overall survival following surgical resection for high-risk localized and locally advanced renal cell carcinoma. Eur. Urol. 80, 20–31 (2021).
Correa, A. F. et al. Predicting renal cancer recurrence: defining limitations of existing prognostic models with prospective trial-based validation. J. Clin. Oncol. 37, 2062–2071 (2019).
Khene, Z.-E. et al. External validation of the ASSURE model for predicting oncological outcomes after resection of high-risk renal cell carcinoma (RESCUE Study: UroCCR 88). Eur. Urol. Open Sci. 33, 89–93 (2021).
Thompson, R. H. et al. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J. Urol. 177, 477–480 (2007).
Vasudev, N. S. et al. UK multicenter prospective evaluation of the Leibovich score in localized renal cell carcinoma: performance has altered over time. Urology 136, 162–168 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G.D.S. declares educational grants from Pfizer, AstraZeneca and Intuitive Surgical; consultancy fees from Pfizer, Merck, EUSA Pharma and CMR Surgical; travel expenses from Pfizer; and speaker fees from Pfizer. J.A.U.-S. declares no competing interests.
Additional information
Related links
Predict Prostate: https://prostate.predict.nhs.uk/
Rights and permissions
About this article
Cite this article
Usher-Smith, J.A., Stewart, G.D. Predicting cancer outcomes after resection of high-risk RCC. Nat Rev Urol 19, 257–258 (2022). https://doi.org/10.1038/s41585-022-00568-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-022-00568-3